Quest Diagnostics Stock News

Quest's second "Know Your Health" survey explores Americans' perceptions and priorities on their well-being in 2025 Nearly one-third of Americans say their doctors/HCPs do not take the time to discuss preventive care and wellness with them; More than half of millennials, Gen Z cite barriers to accessing medical care SECAUCUS, N.J. , May 20, 2025 /PRNewswire/ -- questhealth.com, the consumer-ini...

SECAUCUS, N.J. , May 16, 2025 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, announced that Jim Davis, Chairman, CEO and President, will speak on the company's strategy, performance and the latest market developments and trends during a presentation at the William Blair 45th Annual Growth Stock Conference in Chicago on Tuesday, June 3, 2...

SECAUCUS, N.J. , May 14, 2025 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, today announced that its Board of Directors declared a quarterly cash dividend of $0.80 per share, payable on July 21, 2025 to shareholders of record of Quest Diagnostics common stock on July 7, 2025.

More than 3 in 4 oncologists (76%) feel they are seeing more advanced cancers, and of these, 75% believe that screening barriers are the leading cause, although nearly one-third (32%) cite "factors that we don't understand yet" Missed/delayed follow-up care or monitoring appointments by patients (68%) and imaging tests not detecting recurrence early enough (50%) are among the primary reasons ca...

Quest Diagnostics excels in scale, scope, and service quality, leveraging automation and distribution to reduce costs and offer comprehensive test menus. Despite its strengths, I recommend waiting to buy DGX at $140 for a 15% IRR, as the current valuation is high. Valuation analysis shows DGX trading at a premium; base case IRR is 8.46%, below my 15% threshold, warranting a Hold rating.

Quest Diagnostics Incorporated (NYSE:DGX ) Q1 2025 Results Conference Call April 22, 2025 8:30 AM ET Company Participants Shawn Bevec - Vice President of Investor Relations Jim Davis - Chairman, Chief Executive Officer, President Sam Samad - Chief Financial Officer Conference Call Participants Luke Sergott - Barclays Kevin Caliendo - UBS Patrick Donnelly - Citi Elizabeth Anderson - Evercore ISI...

Laboratory operator Quest Diagnostics beat Wall Street estimates for first-quarter profit on Tuesday, helped by robust demand for its diagnostic tests.

Quest Diagnostics Inc.'s stock fell 3.6% early Tuesday, after the company posted better-than-expected first-quarter earnings and backed its guidance, but said the early part of the quarter was slow.